PsychoGenics Inc. Company Profile
PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics to provide innovative solutions for central nervous system drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions, and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntington's Disease, psychosis/schizophrenia, and Spinal Muscular Atrophy (SMA). The Companyâs in-house discovery efforts have focused on psychiatric indications.
Location
765 Old Saw Mill River Road
Tarrytown
New York
10591
United States of America
Contact
Phone: 914-593-0640
Fax: 914-593-0645
Email: info@psychogenics.com
News Articles
PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
Dyskinesia promise for PsychoGenics' eltoprazine
The private US company PsychoGenics has reported Phase II data suggesting that its selective 5HT1a/1b partial agonist eltoprazine could be an effective treatment for levodopa-induced dyskinesia in Par...
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jun 12, 2012 - PsychoGenics Inc. today reported positive results from a clinical study of eltoprazine in levodopa induced dyskinesia (LID) in Parkinson's disease (P...
PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion
PsychoGenics today announced that the Food and Drug Administration (FDA) has accepted Sunovion’s IND for SEP360, triggering a milestone payment to PsychoGenics, and that human d...
PsychoGenics, Dainippon Sumitomo deal
PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in ...
Afraxis and PsychoGenics Form Alliance to Offer Afraxis' ESP Technology for Drug Discovery
SAN DIEGO and TARRYTOWN, New York, July 16, 2012 /PRNewswire/ -- Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of Psych...
Drugs and Medications
None
PubMed Articles
Triple reuptake inhibitors (TRIs) that block the dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters, are being developed as a new class of antidepressant that may have better effi...
Impulsivity is a heterogeneous construct according to clinical and preclinical behavioural measures and there is some preliminary evidence indicating distinct neurobiological substrates underlying the...
RATIONALE: Nicotinic acetylcholine receptor (nAChR) agonists, partial agonists, and antagonists have antidepressant-like effects in rodents and reduce symptoms of depression in humans. OBJECTIVES: The...
Clinical Trials
None
Companies
PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics...
Psylin Neurosciences, Inc. was formed in January, 2007 as a 50/50 joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Psylin's mission is to pioneer the...
More Information about "PsychoGenics Inc." on BioPortfolio
We have published hundreds of PsychoGenics Inc. news stories on BioPortfolio along with dozens of PsychoGenics Inc. Clinical Trials and PubMed Articles about PsychoGenics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PsychoGenics Inc. Companies in our database. You can also find out about relevant PsychoGenics Inc. Drugs and Medications on this site too.
